Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 3. Rapid correction of low vitamin D status in nursing home residents 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesLess weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients—The PREDICTIVE BMI clinical trial
Diabetic Medicine, 08/20/08
Montanana C et al. - PREDICTIVE BMI was the first study to examine the effect of once-daily detemir with weight as the primary endpoint in a large population of overweight Type 2 diabetes patients. Use of once-daily detemir for intensification of insulin therapy resulted in less weight gain, less hypoglycaemia and equivalent glycaemic control compared with NPH.
| Previous Article | Next Article |
Today in Diabetes...keeping you current
Receive free subspecialty "5-minute updates" via email
Impact of androgen deprivation therapy on cardiovascular disease and diabetes
Journal of Clinical Oncology, 06/12/09
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet - Early Online Publication, 06/09/09
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet, 06/23/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Denosumab update
Current Opinion in Rheumatology, 06/11/09
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)
The American Journal of Cardiology, 06/22/09
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet - Early Online Publication, 06/09/09
Sponsor
Article Search
Sponsor